docosan-3-one | 118477-40-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: docosan-3-one
• 英文别名: Docosan-3-on；Docosan-3-one
• CAS: 118477-40-0
• 化学式: C₂₂H₄₄O
• 分子量: 324.591
• InChiKey: MKBZYNGIDYALQY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  10
• 重原子数：
  23
• 可旋转键数：
  19
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.95
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  docosan-3-one 在 lithium aluminium tetrahydride 、 乙醚 作用下， 生成 docosan-3-ol
  参考文献：
  名称：

  Baykut; Oezeris, Istanbul Universitesi Fen Fakultesi Mecmuasi, Seri C: [Astronomi-Fizik-Kimya], 1957, vol. 22, p. 32,34,35

  摘要：

  DOI：
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 、 alkaline earth salt of/the/ methylsulfuric acid 生成 docosan-3-one
  参考文献：
  名称：

  Baykut; Oezeris, Istanbul Universitesi Fen Fakultesi Mecmuasi, Seri C: [Astronomi-Fizik-Kimya], 1956, vol. 21, p. 102,104,106

  摘要：

  DOI：

文献信息

• Opioid receptor antagonist prodrugs
  申请人：Nirsum Laboratories, Inc.

  公开号：US10544154B2

  公开（公告）日：2020-01-28

  Provided herein are prodrugs of opioid receptor antagonists such as nalmefene and naltrexone, pharmaceutical compositions comprising said compounds, and methods for using said compounds for the treatment of behavioral disorders.

  本文提供了阿片受体拮抗剂（如纳美芬和纳曲酮）的原药、包含所述化合物的药物组合物以及使用所述化合物治疗行为紊乱的方法。
• Breusch; Baykut, Chemische Berichte, 1957, vol. 90, p. 526,528,531
  作者：Breusch、Baykut

  DOI：——

  日期：——
• COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF AGENTS
  申请人：ModernaTX, Inc.

  公开号：US20210198200A1

  公开（公告）日：2021-07-01

  The disclosure features amino lipids and compositions involving the same. Nanoparticle compositions include an amino lipid as well as additional lipids such as phospholipids, structural lipids, PEG lipids, or a combination thereof. Nanoparticle compositions further including therapeutic and/or prophylactic agents such as RNA are useful in the delivery of therapeutic and/or prophylactic agents to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.
• [EN] POLYNUCLEOTIDES ENCODING α-GALACTOSIDASE A FOR THE TREATMENT OF FABRY DISEASE<br/>[FR] POLYNUCLÉOTIDES CODANT POUR L'Α-GALACTOSIDASE A POUR LE TRAITEMENT DE LA MALADIE DE FABRY
  申请人：MODERNATX INC

  公开号：WO2017201328A1

  公开（公告）日：2017-11-23

  The invention relates to mRNA therapy for the treatment of Fabry disease. mRNAs for use in the invention, when administered in vivo, encode human the α-galactosidase A (GLA), isoforms thereof, functional fragments thereof, and fusion proteins comprising GLA. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GLA expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GLA activity in subjects, namely Gb3 and lyso-Gb3.
• [EN] BRANCHED TAIL LIPID COMPOUNDS AND COMPOSITIONS FOR INTRACELLULAR DELIVERY OF THERAPEUTIC AGENTS<br/>[FR] COMPOSÉS LIPIDIQUES DE QUEUE RAMIFIÉS ET COMPOSITIONS POUR L'ADMINISTRATION INTRACELLULAIRE D'AGENTS THÉRAPEUTIQUES
  申请人：MODERNATX INC

  公开号：WO2021055833A1

  公开（公告）日：2021-03-25

  The application relates to lipids of Formula (A), Formula (B) and Formula (1-1), and to lipid nanoparticles (empty or loaded LNPs) including such a lipid as well as additional lipids such as phospholipids, structural lipids, and PEG lipids. Lipid nanoparticles further including therapeutic and/or prophylactics such as RNA are useful in the delivery of therapeutic and/or prophylactics to mammalian cells or organs to, for example, regulate polypeptide, protein, or gene expression.